Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

International Journal of Clinical Oncology

Volumn 16, Issue 3, 2011, Pages 210-220

  Hagihara, Hiroaki ^a   Nouso, Kazuhiro ^a   Kobayashi, Yoshiyuki ^a   Iwasaki, Yoshiaki ^a   Nakamura, Shinichiro ^a   Kuwaki, Kenji ^a   Toshimori, Junichi ^a   Miyatake, Hirokazu ^a,b   Ohnishi, Hideki ^a   Shiraha, Hidenori ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Mitoyo General Hospital   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; PEG IFN; Recurrence; Survival

Indexed keywords

ALBUMIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALAISE; MALE; MICROWAVE THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT CANCER; RETINOPATHY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80051767247     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0150-x     Document Type: Article

References (41)

1. Tsukuma H, Hiyama T, Tanaka S et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801. (Pubitemid 23174709)
2. Takano S, Yokosuka O, Imazeki F et al (1995) Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21:650-655.
3. Shiratori Y, Shiina S, Imamura M et al (1995) Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 22:1027-1033.
4. Ikeda K, Saitoh S, Tsubota A et al (1993) Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer (Phila) 71:19-25. (Pubitemid 23019276)
5. Tateishi R, Shiina S, Teratani T et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer (Phila) 103:1201-1209. (Pubitemid 40328091)
6. Mazziotti A, Grazi GL, Cavallari A (1998) Surgical treatment of hepatocellular carcinoma on cirrhosis: a Western experience. Hepatogastroenterology 45(suppl 3):1281-1287. (Pubitemid 28372114)
7. Livraghi T, Goldberg SN, Lazzaroni S et al (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210:655-661. (Pubitemid 29124024)
8. Kubo S, Nishiguchi S, Shuto T et al (1999) Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 90:162- 170. (Pubitemid 29112316)
9. Kumada T, Nakano S, Takeda i et al (1997) Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25:87-92. (Pubitemid 27014990)
10. Shimada M, Takenaka K, Gion T et al (1996) Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111:720-726. (Pubitemid 26293238)
11. Nagasue N, Uchida M, Makino Y et al (1993) Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 105:488-494. (Pubitemid 23213535)
12. Davis GL, Balart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321:1501-1506. (Pubitemid 20015540)
13. Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510.
14. Nishiguchi S, Kuroki T, Nakatani S et al (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055.
15. Yu ML, Lin SM, Chuang WL et al (2006) A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 11:985- 994.
16. Tanaka H, Tsukuma H, Kasahara A et al (2000) Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 87:741-749. (Pubitemid 30620419)
17. Shiratori Y, Shiina S, Teratani T et al (2003) Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306. (Pubitemid 36205926)
18. Kubo S, Nishiguchi S, Hirohashi K et al (2001) Effects of longterm postoperative interferon alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967. (Pubitemid 32466235)
19. Kubo S, Nishiguchi S, Hirohashi K et al (2002) Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418-422. (Pubitemid 34595504)
20. Mazzaferro V, Romito R, Schiavo M et al (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:1543-1554. (Pubitemid 44970357)
21. Lin SM, Lin CJ, Hsu CW et al (2003) Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer (Phila) 100:376-382.
22. Lo CM, Liu CL, Chan SC et al (2007) A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831-842. (Pubitemid 46809282)
23. Ikeda K, Arase Y, Saitoh S et al (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232. (Pubitemid 30614654)
24. Sun HC, Tang ZY, Wang L et al (2006) Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 132:458-465.
25. Sakaguchi Y, Kudo M, Fukunaga T et al (2005) Low-dose, longterm, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 48:64-70. (Pubitemid 40529213)
26. Suou T, Mitsuda A, Koda M et al (2001) Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 20:301-311. (Pubitemid 32573892)
27. Hung CH, Lee CM, Wang JH et al (2005) Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 20:1553-1559.
28. Jeong S, Aikata H, Katamura Y et al (2007) Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 13:5188-5195. (Pubitemid 47527735)
29. Kudo M, Sakaguchi Y, Chung H et al (2007) Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 72(suppl 1):132-138. (Pubitemid 350256677)
30. Someya T, Ikeda K, Saitoh S et al (2006) Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virusrelated cirrhosis. J Gastroenterol 41:1206-1213. (Pubitemid 46487211)
31. Cammà C, Di Bona D, Schepis F et al (2004) Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 39:333-342. (Pubitemid 38222174)
32. Lindsay KL, Trepo C, Heintges T et al (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403. (Pubitemid 32702353)
33. Kumada H, Okanoue T, Onji M et al (2010) The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour, Welfare of Japan. Guidelines for the treatment of chronic hepatitis, cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 40:8-13.
34. Parsons LS, Ovation Research Group (2001) Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. SAS Institute Inc., Cary, pp 214-226.
35. Hisaka T, Yano H, Ogasawara S et al (2004) Interferon-alpha- Con1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 41:782-789. (Pubitemid 39434308)
36. Ogasawara S, Yano H, Momosaki S et al (2007) Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interferon Cytokine Res 27:507-516. (Pubitemid 46986598)
37. Nakaji M, Yano Y, Ninomiya T et al (2004) IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis (Oxf) 25:389-397. (Pubitemid 38344406)
38. Yano H, Ogasawara S, Momosaki S et al (2006) Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 26:964-975. (Pubitemid 44323415)
39. Miki A, Yano Y, Kato H et al (2008) Anti-tumor effect of pegylated interferon in the rat hepatocarcinogenesis model. Int J Oncol 32:603-608. (Pubitemid 351330466)
40. Chung RT, Andersen J, Volberding P et al (2004) Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351:451-459. (Pubitemid 38988594)
41. Carrat F, Bani-Sadr F, Pol S et al (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292:2839-2848. (Pubitemid 39628231)